Clinical trial
A Multicenter, Prospective, Randomized, Parallel-controlled Clinical Study of Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment Alone for the First-line Treatment of Patients With Cancer-related Fatigue In Gastric Or Colorectal Cancer
NCT06830018 is registered in ClinicalTrials.gov with Changchun GeneScience Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Prospective, Randomized, Parallel-controlled Clinical Study of Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment Alone for the First-line Treatment of Patients With Cancer-related Fatigue In Gastric Or Colorectal Cancer
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- January 23, 2025
- Completion date
- July 31, 2026
- Enrollment
- 76 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cancer-related fatigue， gastric cancer，colorectal cancer，nano-crystalline megestrol acetate，megestrol acetate，first-line treatment